https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Mol. Cancer Ther. 2009 Oct;8(10):2773-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Mol. Cancer Ther. 2009 Oct;8(10):2773-92009-10-01 00:00:002019-02-15 08:59:38An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Brain Pathol. 2009 Oct;19(4):674-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Brain Pathol. 2009 Oct;19(4):674-932009-10-01 00:00:002019-02-15 08:59:39Immunotherapy of diffuse gliomas: biological background, current status and future developments
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-712
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-7122009-10-01 00:00:002021-11-15 14:46:05Dendritic cell therapy of high-grade gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:18-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:18-232009-09-01 00:00:002019-02-15 08:59:38Brain tumor immunotherapy with type-1 polarizing strategies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-08-01 / Stem Cells 2009 Aug;27(8):1734-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-08-01 / Stem Cells 2009 Aug;27(8):1734-402009-08-01 00:00:002019-02-15 08:46:46Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Expert Opin Investig Drugs 2009 Apr;18(4):509-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Expert Opin Investig Drugs 2009 Apr;18(4):509-192009-04-01 00:00:002019-02-15 08:46:47DCVax-Brain and DC vaccines in the treatment of GBM
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-13 / Neurosurg Rev 2009 Jul;32(3):265-73; discussion 273
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-13 / Neurosurg Rev 2009 Jul;32(3):265-73; discussion 2732009-02-13 00:00:002019-02-15 08:59:41Dendritic-cell- and peptide-based vaccination strategies for glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Drugs 2009;69(3):241-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Drugs 2009;69(3):241-92009-01-01 00:00:002019-02-15 08:46:48Tumour vaccine approaches for CNS malignancies: progress to date
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-18 / Neurol. Res. 2009 Feb;31(1):3-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-18 / Neurol. Res. 2009 Feb;31(1):3-102008-10-18 00:00:002019-02-15 09:00:15Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-15 / Cancer Res. 2008 Jul;68(14):5955-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-15 / Cancer Res. 2008 Jul;68(14):5955-642008-07-15 00:00:002019-02-15 08:46:49Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients